methsuximide

Methsuximide is a succinimide anticonvulsant medication marketed as a racemate under the tradenames Petinutin and Celontin. Methsuximide its therapeutic efficacy is largely attributed to its active metabolite N-desmethylmethosuximide, which has a longer half-life and achieves higher plasma concentrations, making it central to the studies of epilepsy pharmacotherapy and metabolite-driven drug action.

Methsuximide (Standard) is a reference standard for research and analysis in studies involving Methsuximide. Methsuximide is an anticonvulsant agent which appeared to be effective in petit mal, psychomotor and focal motor attacks [1].